News & Blog

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich’s Ataxia

February 2025 – Advocacy Newsletter Copy

Job Posting: Development Manager (Major Gifts)

Job Posting: Communications & Social Media Coordinator 

Meet the Community 2: A Closer Look – Matthew LaFleur

Letter to the FA Community from Astellas Pharma

Meet The Community: Christin Haun

Webinar Recording: PTC Therapeutics Vatiquinone Program January 2025 Update

Janaury 2025 – Advocacy Newsletter

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

Living with FA, Leading in Research: FA Patient-Researchers Present at ICAR 2024